BioCentury
ARTICLE | Clinical News

IV TRC105: Phase I data

June 8, 2009 7:00 AM UTC

Data from 19 patients in a dose-escalation Phase I trial showed that 0.01-1.0 mg/kg IV TRC105 resulted in 5 cases of stable disease. The compound was well tolerated, with 1 case of grade 4 gastric ulc...